ArticleFrontiers in pharmacology2025

Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system.

Chengyu Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.